Abstract: The present invention relates to plant-produced angiogenins, to related plant cells, plant calli, plants, seeds and other plant parts and products derived therefrom and to uses of plant-produced angiogenins. The present invention also relates to expression of angiogenin genes in plants and to related nucleic acids, constructs and methods.

Abstract: The present invention relates to plant-produced angiogenins, to related plant cells, plant calli, plants, seeds and other plant parts and products derived therefrom and to uses of plant-produced angiogenins. The present invention also relates to expression of angiogenin genes in plants and to related nucleic acids, constructs and methods.

Abstract: The present invention relates to plant-produced angiogenins, to related plant cells, plant calli, plants, seeds and other plant parts and products derived therefrom and to uses of plant-produced angiogenins. The present invention also relates to expression of angiogenin genes in plants and to related nucleic acids, constructs and methods.

Abstract: The present invention relates to plant-produced angiogenins, to related plant cells, plant calli, plants, seeds and other plant parts and products derived therefrom and to uses of plant-produced angiogenins. The present invention also relates to expression of angiogenin genes in plants and to related nucleic acids, constructs and methods.

Abstract: The present invention relates to plant-produced angiogenins, to related plant cells, plant calli, plants, seeds and other plant parts and products derived therefrom and to uses of plant-produced angiogenins. The present invention also relates to expression of angiogenin genes in plants and to related nucleic acids, constructs and methods.

Abstract: The present invention relates to plant-produced angiogenins, to related plant cells, plant calli, plants, seeds and other plant parts and products derived therefrom and to uses of plant-produced angiogenins. The present invention also relates to expression of angiogenin genes in plants and to related nucleic acids, constructs and methods.

Abstract: The present invention provides polynucleotide and amino acid sequences which encode and identify a novel human myeloid terminal differentiation response gene designated MYD118. The present invention also provides for myd118 antisense molecules. The invention further provides genetically engineered expression vectors and host cells for the production of purified MYD118 polypeptide; antibodies, antagonists and inhibitors of MYD118 polypeptide; and pharmaceutical compositions and methods of treatment based on polynucleotide sequences encoding MYD118 and MYD118 polypeptide. The invention specifically provides for use of the myd118 polynucleotide sequences as a diagnostic composition for the detection of myeloproliferative diseases and leukemias. The invention also relates to therapeutic methods and compositions based upon the nucleotide sequences for myd118. The invention further provides antibodies which specifically bind to MYD118.

Abstract: The present invention relates to purified polynucleotides and a composition comprising a plurality of polynucleotide probes that are modulated in response to cytokines and which are associated with human immune response, conditions, disorders, and diseases. The present invention presents methods for using the polynucleotides, and use of the polynucleotide probes as hybridizable elements in a microarray.

Abstract: The present invention provides a polynucleotide (mctl) which identifies and encodes a novel human C-type lectin (MCTL). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding MCTL. The invention also provides for the use of substantially purified MCTL and its agonists in the commercial production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the expression of MCTL. Additionally, the invention provides for the use of antisense molecules to mctl in pharmaceutical compositions for treatment of diseases associated with the expression of MCTL. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of mctl. The present invention also relates to anti-MCTL antibodies which specifically bind to MCTL.

Abstract: The present invention provides a polynucleotide (mctl) which identifies and encodes a novel human C-type lectin (MCTL). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding MCTL. The invention also provides for the use of substantially purified MCTL and its agonists in the commercial production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the expression of MCTL. Additionally, the invention provides for the use of antisense molecules to mctl in pharmaceutical compositions for treatment of diseases associated with the expression of MCTL. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of mctl. The present invention also relates to anti-MCTL antibodies which specifically bind to MCTL.

Abstract: The present invention provides polynucleotide and amino acid sequences which encode and identify a novel human myeloid terminal differentiation response gene designated MYD118. The present invention also provides for myd118 antisense molecules. The invention further provides genetically engineered expression vectors and host cells for the production of purified MYD118 polypeptide; antibodies, antagonists and inhibitors of MYD118 polypeptide; and pharmaceutical compositions and methods of treatment based on polynucleotide sequences encoding MYD118 and MYD118 polypeptide. The invention specifically provides for use of the myd118 polynucleotide sequences as a diagnostic composition for the detection of myeloproliferative diseases and leukemias. The invention also relates to therapeutic methods and compositions based upon the nucleotide sequences for myd118. The invention further provides antibodies which specifically bind to MYD118.

Abstract: The present invention relates to a heretofore uncharacterized family of cyclic nucleotide phosphodiesterases (CN PCD8) and provides specific polynucleotide and amino acid sequences which encode and identify CN PDE8 family members designated herein as CN PDE8A and CN PDE8B. The present invention also relates to the use of proteins, peptides and organic molecules capable of modulating CN PDE8 activity to inhibit or enhance phosphodiesterase activity associated with disease. The present invention further relates to the use of CN PDE8 and genetically engineered host cells that express CN PDE8 to evaluate and screen for substances and compounds that modulate cyclic nucleotide phosphodiesterase activity. The present invention also provides for cn pde8 antisense molecules. The invention provides genetically engineered expression vectors and host cells for the production of purified CN PDE8 polypeptide.